Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Small Business Innovation Research (SBIR)

The Small Business Innovation Research (SBIR) program is a set-aside program (3.2% of an agency's extramural budget in FY2017) for domestic small business concerns to engage in Research/Research and Development (R/R&D) that has the potential for commercialization and public benefit. The SBIR program was established under the Small Business Innovation Development Act of 1982 (P.L. 97-219). In December of 2011, the program was re-authorized through FY2017 by the 2012 Defense Authorization Act (P.L.112-81).

CDC’S Small Business Innovation Research (SBIR) program functions to promote Research and Development (R&D) from small businesses, where innovation and innovators thrive, in order to effectively support the health promotion and disease prevention needs and goals of CDC.

Today, CDC’s SBIR program is under the stewardship of the Office of the Associate Director for Science, Office of Technology and Innovation (OTI). This office is committed to ensuring a competitive award process that results in projects of scientific excellence and technological innovation with the potential for commercialization.

About the SBIR Program

The SBIR Program was established by Congress  to provide increased opportunities for small businesses to participate in R&D, to increase employment, and to improve U.S. competitiveness.

The program's specific objectives are to:

  • Use small businesses to stimulate technological innovation
  • Strengthen the role of small business in meeting Federal R/R&D needs
  • Increase private sector commercialization of innovations developed through Federal SBIR R&D
  • Increase small business participation in Federal R/R&D
  • Foster and encourage participation by socially and economically disadvantaged small business concerns and women-owned business concerns in the SBIR program

Eligible Institutions/Organizations:

Only United States small business concerns (SBCs) are eligible to submit SBIR applications. A SBC is one that, on the date of award for both Phase I and Phase II funding agreements, meets ALL of the criteria as described in the current SBIR parent funding opportunity announcement available at the NIH Small Business Funding Opportunities website.

Three Phases of SBIR

Funding is awarded competitively and is available for only Phases I and II of the SBIR program:

  • Phase I awards projects up to $150,000 for approximately 6 months to support exploration of the technical merit or feasibility of an idea or technology.
  • Phase II awards projects that expand Phase I results. Awards are for up to $1,000,000 for a time period of up to 2 years. During this time, the R&D work is performed and the developer evaluates commercialization potential.
  • Phase III is the period during which Phase II innovation moves from the laboratory into the marketplace. At this stage, the small business must find funding in the private sector or other non-SBIR funding.

CDC SBIR Funding Opportunities

  1. CDC participates in the PHS 2016-2 SBIR Omnibus FOA (PA-16-302 ) Grant Solicitation with NIH, FDA, and ACF. The first submission date was September 6, 2016. The next submission dates are on January 5, 2017, and April 5, 2017.
  2. CDC participates along with NIH in the PHS 2017-1 SBIR Contract Solicitation. All CDC SBIR Contract proposals are due October 21, 2016 by 5:00PM EDT. Contracts proposals are submitted electronically using the NIH/NIAID Contract Proposal Submission (eCPS) website.

    The HHS SBIR Contract Webinar was held on August, 24, 2016. The webinar included discussion on the PHS 2017-1 solicitation, the electronic contract proposal submission (eCPS) website, and topic overview. The webinar resources are now available online: HHS SBIR Contract RFP Informational Webinar PHS 2017-1.

  3. CDC participates in the I-Corps™ at NIH Program. The I-Corps™ at NIH is modeled after the successful I-Corps™ at NSF and will be leveraged to support innovation with the goal of expediting the development, detection, and therapeutic technologies for the leading causes of death and disability in the United States. I-Corps™ participants will receive capacity building and entrepreneurial trainings, mentorship opportunities, as well as modest funding to assist them in translating their ideas from the lab into a viable product on the market and to help them avoid common failure points.

    Small business Phase I grantees of the following CDC SBIR Programs are eligible and encouraged to apply by November 1, 2016.

    • National Center for Emerging Zoonotic and Infectious Diseases (NCEZID/CDC)
    • National Institute for Occupational Safety and Health (NIOSH/CDC)

    For more information or questions on the I-Corps™ at NIH program, please visit: The I-Corps™ at NIHh

  4. CDC participated in the Commercialization Accelerator Program (CAP), a three-track customized program designed to serve the needs of up to 80 HHS SBIR Phase II Awardees at different levels of commercialization experience and expertise. Funded by the National Institutes of Health (NIH) and managed through a contract with Larta, Inc. (www.larta.org) of Los Angeles, CA, the CAP provides selected participants with individualized assistance towards accomplishing key commercialization goals. This is achieved through individual mentoring and consulting sessions, training workshops, access to domain experts, and focus on outcomes that will enhance the commercialization profile and readiness of participating awardees.

    The application period for CAP is currently CLOSED for the 2016-2017 YEAR. Please continue to check our website in late JULY 2017 to apply for the 2017- 2018 YEAR in August 2017.

    For a list of CDC funded SBIR contracts and grants from FY2013 to FY2015, please see: CDC SBIR Awardees FY2013-FY2015_Final . For more information about individual funded projects, visit the NIH RePORTER.

SBIR Report Fraud, Waste, and Abuse

The Office of Inspector General (OIG) promotes the effective, efficient, and economical operation of Department of Health & Human Services programs and operations through audits, inspections, investigations, and other reviews.The HHS OIG Hotline accepts tips from all sources about potential fraud, waste, abuse, and mismanagement in Department of Health & Human Services programs. The reporting individual should indicate the fraud, waste, and/or abuse concerns for a SBIR grant or contract, if relevant.

Visit the OIG Report Fraud website for additional information.

Please direct all inquiries to: Office of Technology and Innovation, sbir@cdc.gov, 404-718-1386.

  • Page last reviewed: April 7, 2016
  • Page last updated: October 5, 2016
  • Content source:
    • Office of the Associate Director for Science
Top